Primary Insomnia

http://emedicine.medscape.com/article/291573-overview

Primary Insomnia
Author: Catherine McVearry Kelso, MD, MS; Chief Editor: Iqbal Ahmed, MBBS, FRCPsych (UK) more... Updated: Mar 29, 2011

Criteria for Primary Insomnia

Primary insomnia is sleeplessness that is not attributable to a medical, psychiatric, or environmental cause. Below are the diagnostic criteria for primary insomnia as set forth by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). The predominant symptom according to the DSM-IV-TR is difficulty initiating or maintaining sleep, or suffering from nonrestorative sleep, for at least 1 month. The second criterion is that the sleep disturbance (or associated daytime fatigue) causes clinically significant distress or impairment in social, occupational, or other important areas of functioning. The third criterion is that the sleep disturbance not occur exclusively during the course of narcolepsy, breathingrelated sleep disorder, circadian rhythm sleep disorder, or a parasomnia. The fourth criterion is that the disturbance not occur exclusively during the course of another mental disorder (eg, major depressive disorder, generalized anxiety disorder, a delirium). Finally, the fifth criterion is that the disturbance not be due to the direct physiological effects of a substance (eg, drug abuse, medication) or a general medical condition.[1] The International Classification of Sleep Disorders (ICSD-2) diagnostic and coding manual consists of 3 primary insomnia categories: Psychophysiological insomnia Idiopathic insomnia Paradoxical insomnia[2, 3]

Treatment Goals and Considerations

The pathophysiology of primary insomnia is not well understood, and essential features assist in diagnosis. The focus of management is on symptoms.[4] However, findings have strengthened the evidence that primary insomnia may be linked with mood disorders and is associated with hypothalamic-pituitary-adrenal (HPA) axis overactivity and excess secretion of corticotropin-releasing factor (CRF), adrenocorticotropin-releasing hormone, and cortisol. The goal of insomnia management is to improve sleep quality and maintenance and limit daytime impairments.[5, 6, 7] Inpatient care is not usually required for primary insomnia unless significant medical or psychiatric comorbidity exists. Sleep disturbance is a reliable indicator of psychological and/or physical ill health. A report of disturbed sleep from the patient signals the need for further evaluation and close monitoring. Go to Insomnia for more complete information on this topic.

Types of Insomnia
Psychophysiologic insomnia

1 de 11

10/09/11 01:15

Primary Insomnia

http://emedicine.medscape.com/article/291573-overview

The essential features of psychophysiologic insomnia include learned or behavioral insomnia and heightened arousal. The primary components involved are intermittent periods of stress that result in poor sleep and maladaptive behaviors. These include (1) a vicious cycle of trying harder to sleep and becoming more tense (ie, patients trying too hard to sleep) and (2) bedroom habits and routines (eg, brushing teeth) that actually condition the patient to become frustrated and aroused. Patients often report "racing thoughts" and sensitivity to their environment. Bad sleep habits, such as those naturally acquired during periods of stress, are occasionally reinforced. These are therefore not resolved and become persistent. Insomnia continues for years after the stress has abated, and is labeled persistent psychophysiologic insomnia.

Idiopathic insomnia
The essential feature of idiopathic insomnia is lifelong sleeplessness, with onset in infancy or childhood. Idiopathic insomnia can be aggravated by stress or tension. Lifelong sleeplessness is attributed to an abnormality in the neurologic control of the sleep-wake cycle for many areas of the reticular activating system (which promotes wakefulness), as well as in areas such as supra nuclei, raphe nuclei, and medial forebrain areas (which promote sleep). Possibly, a so-called neuroanatomic, neurophysiologic, or neurochemical lesion exists in the sleep state, with patients tending to be on the extreme end of the spectrum toward arousal.

Paradoxical insomnia
Paradoxical insomnia is also called sleep state misperception.[8] The essential feature is reports of severe insomnia without supporting objective evidence, such as daytime sleepiness.

Incidence in the United States

Primary insomnia is diagnosed in approximately 15-25% of patients with insomnia who are referred to sleep disorder centers following exclusion of other predisposing conditions. However, the true incidence is not known. Primary insomnia is estimated to occur in 25% of all patients with chronic insomnia.

Consequences of Primary Insomnia

Whether the consequences associated with chronic insomnia outweigh the costs of treatment remains debatable. Despite that, various health-related associations with chronic insomnia have been noted. Poor health and decreased activity occur in persons with chronic insomnia. Moreover, insomnia is the best predictor of the future development of depression. An increased risk of mortality is associated with short sleep lengths. (Eg, the onset of insomnia in older patients is related to decreased survival.) Catastrophic worry about the consequences of not sleeping is common among patients with chronic insomnia and serves to maintain the sleep disturbance. In persons with chronic insomnia, there is an increased risk for the development of anxiety, alcohol and drug use disorders, and nicotine dependence.

Sex and Age Predilections

Primary insomnia is more common in women than in men. Persons of any age may be affected, although primary insomnia is more common in the older population.[9, 10, 11, 12]

Patient History

2 de 11

10/09/11 01:15

Primary Insomnia

http://emedicine.medscape.com/article/291573-overview

A thorough clinical interview with the patient and his or her sleep partner is critical in making the correct diagnosis of primary insomnia.

Psychophysiologic insomnia
Sleep disturbance in these patients ranges from mild to severe. Insomnia may manifest as difficulty falling asleep or as frequent nocturnal awakenings. Patients often find that they can sleep well anywhere else but in their own bedroom. Patients with this type of insomnia tend to be more tense and dissatisfied compared to people who sleep well. Emotionally, they typically are repressors, denying problems.

Idiopathic insomnia
In patients with this condition, the insomnia is long-standing, typically beginning in early childhood. Patients often present with other hard-to-localize neurologic signs and symptoms, such as difficulty with attention or concentration, hyperactivity, and mild, nonfocal electroencephalographic abnormalities. Emotionally, persons with childhood-onset insomnia are often repressors, denying and minimizing emotional problems. These individuals often show atypical reactions, such as hypersensitivity or insensitivity, to medications.

Paradoxical insomnia
Patients report insomnia subjectively, while sleep duration and quality are completely normal.

Physical Findings in Primary Insomnia

Physical characteristics that indicate sleep deprivation and fatigue can include features such as eye redness. Depending on the origin of the sleep dysfunction, other physical findings would be included to rule out secondary causes (ie, weight, neck circumference, thyroid).

Assessment of Mental Status

A complete neurologic examination is included in the evaluation of insomnia, to assess for comorbid conditions. Recognition of mental disorders that may be contributing to insomnia is key to effectively managing symptoms.[13] When performing a complete Mental Status Examination, drowsiness and mood changes, such as irritability, anxiety, and sad feelings from underlying depression, may be noted. The clinician should also note the patient's orientation, memory, judgment, insight, and the presence of any hallucinations or delusions.[14] As with any mental status (but especially with the concern about depression), assess the patient's suicide potential. For completeness, assess the patient's homicidal potential as well.

Differentials in Primary Insomnia

The exclusion of common causes of insomnia is required to make the diagnosis of primary insomnia. Medical causes of insomnia include the following: Chronic pain, especially neuropathic pain Primary sleep disorders (eg, sleep apnea, periodic limb movements, restless legs syndrome) Dyspnea from any cause Pregnancy Drug use or withdrawal (eg, selective serotonin reuptake inhibitors, stimulants, antihistamines, caffeine, diet pills, herbal preparations containing ma huang, anticonvulsants, steroids) Psychiatric and/or psychological causes of insomnia include the following:

3 de 11

10/09/11 01:15

Primary Insomnia

http://emedicine.medscape.com/article/291573-overview

Anxiety disorders (eg, generalized anxiety, panic attacks, obsessive-compulsive disorder) Substance abuse (eg, alcohol or sedative/hypnotic withdrawal) Major life stressors and/or events Mood disorders (eg, depression, mania) Environmental causes of insomnia include the following: Noise Jet lag or shift work Bedroom too hot or cold Symptoms of the following conditions can mimic those of primary insomnia: Adjustment Disorders Alcohol-Related Psychosis Amphetamine Abuse Anxiety Disorders Apnea, Sleep Bipolar Affective Disorder Caffeine-Related Psychiatric Disorders Circadian rhythm sleep disorder Cocaine-Related Psychiatric Disorders Depression Hyperthyroidism Obstructive Sleep Apnea-Hypopnea Syndrome Parasomnias Postpartum Depression Posttraumatic Stress Disorder Schizophrenia Substance abuse can cause insomnia during the intoxication phase, during the sustained use phase, and during withdrawal.

Diagnostic Studies in Primary Insomnia

Laboratory studies in primary insomnia
Laboratory studies essentially are not required for the diagnosis of primary insomnia. However, tests are required to exclude other causes of insomnia, including the following: Thyroid function tests (hyperthyroidism) Blood alcohol levels (alcohol-related psychosis)

Imaging studies in primary insomnia

Neuroimaging studies may be helpful if a structural lesion is suspected to cause insomnia.

Sleep diary
This is a questionnaire (shown below) completed by the patient each morning to describe the previous night's sleep.

Evaluation of insomnia. Format of sleep diary.

4 de 11

10/09/11 01:15

Primary Insomnia

http://emedicine.medscape.com/article/291573-overview

Data from the sleep diary may help to minimize distortions in sleep information recalled in the physician's office.

Actigraphy
This technique makes use of an activity monitor to record activities during sleep and waking. It is useful in the diagnosis of circadian rhythm sleep disorders, sleep state misperception, and other types of primary insomnia. In older adults treated for chronic primary insomnia, the clinical use of actigraphy is still suboptimal in detecting wakefulness.[15]

Full-night polysomnography
Full-night polysomnography (PSG) is indicated when suspicion of sleep apnea or movement disorders arises, when initial diagnosis is uncertain, when treatment fails, or when precipitous arousal occurs with violent or injurious behavior.[16, 17, 18, 15]

Multiple sleep latency test

Psychophysiologic insomnia and idiopathic insomnia manifest as increased sleep latency, reduced sleep efficiency, and an increase in the number and duration of awakenings. Sleep state misperception manifests as normal sleep latency (15-20 min), normal number of arousals and awakenings, and normal sleep duration (6.5 h). The multiple sleep latency test shows normal daytime vigilance. Sleep state misperception can be diagnosed only in the laboratory because of the need to document that sleep duration and quality are normal when a person claims to have poor sleep.

Nonprescription Drug Therapy

The active agent in many over-the-counter medications is one of the sedating antihistamines. These medications are generally safe but have anticholinergic adverse effects, such as dry mouth, blurred vision, urinary retention, and confusion in older patients, that can be potentially more serious in patients with dental caries, glaucoma, prostatic enlargement, and dementia (or delirium), respectively. These medications are minimally effective in inducing sleep and may reduce sleep quality. Discourage patients from using them on a routine basis. The use of various herbal preparations (eg, herbal tea) and nutritional substances are reported to be beneficial by users, but no supporting trials have been performed. Studies have shown that melatonin may be useful for short-term adaptation to jet lag or other circadian rhythm sleep disorders. One study showed that ramelteon, a highly selective agonist for melatonin subtypes 1 and 2 receptors, is a good option for the treatment of insomnia characterized by difficulty falling asleep. In patients with insomnia, treatment with ramelteon was generally well tolerated and resulted in modest, but statistically significant, decreases in the latent period for sleep.[19] Ramelteon was the first melatonin receptor agonist drug to have been approved by the US Food and Drug Administration (FDA).[20]

Prescription Drug Therapy

Patients need to be observed closely and have regular follow-up visits to review their response to and any adverse effects from drugs used to treat insomnia. The American Academy of Sleep Medicine guidelines include the following recommendations for the pharmacologic management of primary insomnia, listed in the following preferred medication sequence:[16] Short- or intermediate-acting benzodiazepine receptor agonists (BzRAs), whether a benzodiazepine such as temazepam or a newer BzRA, such as zolpidem, eszopiclone, or zaleplon Other short- or intermediate-acting BzRAs or ramelteon if the initial agent was unsuccessful Sedating low-dose antidepressant, such as trazodone, nefazodone, amitriptyline, doxepin, and

5 de 11

10/09/11 01:15

Primary Insomnia

http://emedicine.medscape.com/article/291573-overview

mirtazapine,[21] especially in patients with depression or anxiety Combination BzRA or ramelteon and sedating antidepressant Amitriptyline should not be used in older patients because of a high anticholinergic side-effect profile. According to evidence-based recommendations on sleep disorders in older persons published in the Journal of American Geriatrics Society in 2009, clinically significant adverse effects can be associated with all FDA-approved medications for the treatment of insomnia (evidence level A), and the safest and most effective medications currently available are nonbenzodiazepines and melatonin receptor agonists (evidence level B or moderate).[22, 20] Prescriptions not recommended include the following:[16] Chloral hydrate, barbiturates, and nonbarbiturate nonbenzodiazepine drugs (ie, meprobamate), due to significant adverse effects and tolerance Off-label use of antiepileptic (gabapentin, tiagabine) and atypical antipsychotics (quetiapine, olanzapine) Regarding the above recommendation against the off-label use of antiepileptic and atypical antipsychotic drugs, there is Insufficient evidence of efficacy when these agents are used alone, and adverse effects can occur. They may be considered for patients with comorbid conditions and insomnia. Basic principles for the rational treatment of insomnia are to use the lowest effective dose, use intermittent dosing (2-3 nights/wk), use short term (2-3 wk at a time), discontinue after slow taper if the patient has been taking it regularly, and use agents with short and/or intermediate half-life to minimize daytime sedation. (See the table below.) Pharmacokinetic properties and risk-benefit ratio are the key factors in selecting the most appropriate medication.[23] Table 1. FDA-Approved Hypnotics for Insomnia (Open Table in a new window) Trade Name 15-30 mg 7.5-15 mg 1-2 mg 7.5-30 mg 0.5-4 mg; 1 mg in elderly 0.125-0.5 mg

Duration Benzodiazepine Long acting

Agent

Dose

Half-life

Comments

Flurazepam Dalmane Quazepam Doral ProSom

48-120 h 41 h

Do not use in older adults due to long half-life Do not use in older adults due to long half-life

Intermediate acting

Estazolam

10-24 h Sleep maintenance 3.5-18 h Sleep maintenance 12-20 h May be used if duration of action meets patients needs 1.5-5.5 h 6h 2.5 h 2.8 h Caution, rebound anxiety; not first-line agent Sleep onset and maintenance Primary use, sleep onset Primary use, sleep onset and maintenance Primary use, sleep onset; maintenance up to 4 h

Temazepam Restoril Lorazepam* Ativan

Short acting

Triazolam

Halcion

Nonbenzodiazepine Intermediate acting Shortto-intermediate Eszopiclone Lunesta Zolpidem Zolpidem ER Short acting Zaleplon Ambien Ambien CR Sonata 2-3 mg; 1 mg in elderly and hepatic impairment 5-10 mg; 5 mg in elderly or hepatic impairment 12.5 mg; 6.25 mg in elderly or hepatic impairment

10 mg, 5 mg in elderly or 0.9-1 h hepatic impairment or use with cimetidine 8 mg 1-2.6 h

Melatonin Receptor Agonist Short acting Ramelteon Rozerem Primary use, sleep onset

6 de 11

10/09/11 01:15

Primary Insomnia

http://emedicine.medscape.com/article/291573-overview

* Not FDA approved for sleep

Common adverse effects of hypnotics

Anterograde amnesia and withdrawal effects may occur, especially with short-acting BZD (not with zolpidem and zaleplon). Residual daytime sedation with intermediate-acting and long-acting drugs may occur, depending on dosage and half-life. Rebound insomnia may occur with short-acting and intermediate-acting BZD after discontinuation.

Recommendations in the administration of hypnotics

Dosage, pharmacokinetic properties, and risk-benefit ratio are the key factors in selecting the most appropriate medication. Short-acting agents are recommended for patients with difficulty falling asleep, while intermediate-acting drugs are indicated for problems with sleep maintenance. Avoid long-acting agents, especially in older people, because they cause daytime sedation and impair cognition, thereby increasing the risk of falls. Caution and close monitoring is needed in the administration of hypnotics to older people and to patients with hepatic, renal, or pulmonary disease.

Contraindications to hypnotic use

Contraindications of these agents are as follows: Pregnancy Untreated obstructive sleep apnea History of substance abuse

Potential insomnia medications

New experimental drugs have been under investigation as possible insomnia treatments.[24, 25] For example, initial studies of indiplon showed significant improvement in subjective measures of sleep induction and maintenance in elderly women with chronic insomnia, at a dose of 5-10 mg. Indiplon is a unique nonbenzodiazepine experimental drug that acts on a specific site of the gamma-aminobutyric acid (GABA)-A receptor.[26, 27] A randomized, double-blind, placebo-controlled trial using low-dose doxepin for elderly patients with primary insomnia revealed improved sleep maintenance and some effect on sleep onset, at doses of 1 mg, 3 mg and 6 mg, with no anticholinergic side effects. Doxepin is a histamine-H(1) antagonist.[28]

Nonpharmacologic Treatment
Psychological treatment for insomnia consists primarily of patient education and short-term cognitive-behavioral therapies. The focus is primarily on sleep hygiene or factors presumed to perpetuate insomnia. These therapies seek to modify maladaptive sleep habits and to educate patients about healthier sleep practices.[29]

Stimulus control therapy

The purpose of this treatment is to reestablish the connection between the bed and sleep by prohibiting the patient from engaging in nonsleep activities while in bed. The instructions given to the patient are (1) to go to bed only when sleepy, (2) to use the bed and bedroom only for sleep and intimacy, (3) to avoid trying to force sleep (go into another room whenever unable to fall asleep within 20-30 min and return to bed only when sleepy again), (4) to get up at the

7 de 11

10/09/11 01:15

Primary Insomnia

http://emedicine.medscape.com/article/291573-overview

same time each morning regardless of how much the patient slept the previous night, and (5) to avoid daytime napping.

Sleep restriction therapy

This involves limiting the amount of time the patient spends in bed to the actual amount of time the patient usually spends sleeping. This results in sleep deprivation, which accumulates and causes more rapid sleep onset on subsequent nights. As sleep improves, the patient is allowed to gradually increase time in bed by 15-30 minutes.

Relaxation therapies
Relaxation-based interventions are indicated based on the observation that patients with insomnia often display high levels of arousal (physiologic and cognitive) at night and during the daytime. The various techniques available to deactivate the arousal system are (1) progressive muscle relaxation, (2) biofeedback, and (3) imagery training and thought stopping.

Cognitive behavior therapy

Cognitive behavior therapy (CBT) consists of identifying patient-specific dysfunctional sleep cognitions, challenging their validity, and replacing them with more adaptive substitutes, such as reattribution training, reappraisal, and attention shifting. A randomized clinical trial determined that 4 individual, biweekly sessions represent the optimal dosing for cognitive behavioral intervention.[30]

Paradoxical intention
This method consists of persuading a patient to engage in his or her most feared behavior (ie, staying awake). This serves to eliminate performance anxiety so that sleep may come more easily.

Combined therapy
CBT and hypnotic medications are efficacious for short-term treatment of insomnia, but few patients achieve complete remission with any single treatment. Morin et al studied 160 adults with persistent insomnia and demonstrated that CBT used singly or in combination with zolpidem produced significant improvements in sleep latency, time awake after sleep onset, and sleep efficiency during initial therapy. Combined therapy produced a higher remission rate compared with CBT alone during the 6-month extended therapy phase and the 6-month follow-up period (56% [43/74 and 32/59] vs 43% [34/75 and 28/68]). The long-term outcome was optimized when medication was discontinued during maintenance CBT.[31]

Consultations in Primary Insomnia

Consultation with a sleep disorders specialist may be necessary if the standard pharmacologic and behavioral treatments are not effective.

Patient Information
The following sleep hygiene recommendations, which include environmental and lifestyle modifications, should be used as an adjunct to other forms of therapy: Elimination of the use of caffeine, especially after noon No tobacco or alcohol use near bedtime Avoidance of heavy meals close to bedtime (may eat a light snack at bedtime) Engagement in exercise early in the day before dinner to alleviate stress, but not before bedtime Avoidance of daytime naps and establishment of a regular schedule for going to bed and getting up Maintenance of the bedroom at a comfortable temperature, and minimization of light and noise Family education and patient self-help information are also important. Resources on sleep disorders can be found at

8 de 11

10/09/11 01:15

Primary Insomnia

http://emedicine.medscape.com/article/291573-overview

the National Sleep Foundation Web site. For patient education information, see eMedicine's Mental Health and Behavior Center and Sleep Disorders Center. As well as Primary Insomnia, Insomnia, Disorders That Disrupt Sleep (Parasomnias), Understanding Insomnia Medications, Sleep Disorders in Women, Sleep Disorders and Aging, and Sleeplessness and Circadian Rhythm Disorder.

Contributor Information and Disclosures

Author Catherine McVearry Kelso, MD, MS Associate Professor of Internal Medicine, Virginia Commonwealth University School of Medicine; Medical Director, Hospice and Palliative Care, Site Director, Palliative Care Fellowship, Ethics Consultation Coordinator, Hunter Holmes McGuire Veterans Affairs Medical Center Catherine McVearry Kelso, MD, MS is a member of the following medical societies: American Academy of Hospice and Palliative Medicine, American Geriatrics Society, and American Society for Bioethics and Humanities Disclosure: Nothing to disclose. Coauthor(s) Antony Fernandez, MD, FRCPsych (UK) Professor of Psychiatry, Virginia Commonwealth University School of Medicine; Attending Physician, Mental Health Service, McGuire Veterans Affairs Medical Center, Richmond Antony Fernandez, MD, FRCPsych (UK) is a member of the following medical societies: American Society of Addiction Medicine Disclosure: Nothing to disclose. Angela Gentili, MD Director of Geriatrics Fellowship Program, Associate Professor, Department of Internal Medicine, Virginia Commonwealth University Health System and McGuire Veterans Affairs Medical Center Angela Gentili, MD is a member of the following medical societies: American Geriatrics Society Disclosure: Nothing to disclose. Specialty Editor Board Jennifer S Morse, MD Associate Medical Director, Optum Health Jennifer S Morse, MD is a member of the following medical societies: Academy of Psychosomatic Medicine, Aerospace Medical Association, and American Psychiatric Association Disclosure: Nothing to disclose. Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference Disclosure: Medscape Salary Employment Chief Editor Iqbal Ahmed, MBBS, FRCPsych (UK) Faculty, Department of Psychiatry, Tripler Army Medical Center; Clinical Professor of Psychiatry, Clinical Professor of Geriatric Medicine, University of Hawaii, John A Burns School of Medicine Iqbal Ahmed, MBBS, FRCPsych (UK) is a member of the following medical societies: Academy of Psychosomatic Medicine, American Association for Geriatric Psychiatry, American Neuropsychiatric Association, American Psychiatric Association, American Society of Clinical Psychopharmacology, and Royal College of Psychiatrists Disclosure: Nothing to disclose. Acknowledgments The authors and editors of eMedicine gratefully acknowledge the contributions of previous authors Aparna

9 de 11

10/09/11 01:15

Primary Insomnia

http://emedicine.medscape.com/article/291573-overview

Ranjan, MD, and Kirk L Nelson, MD, to the development and writing of the source article.

References
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Press; 2000:553-557. 2. International Classification of Sleep Disorders, 2nd ed: Diagnostic and Coding Manual. ISBN 0-9657220-1-5 [database online]. Westchester, IL: American Academy of Sleep Medicine; 2005. 3. Silber MH. Clinical practice. Chronic insomnia. N Engl J Med. Aug 25 2005;353(8):803-10. [Medline]. 4. Roth T, Roehrs T, Pies R. Insomnia: pathophysiology and implications for treatment. Sleep Med Rev. Feb 2007;11(1):71-9. [Medline]. 5. Budur K, Rodriguez C, Foldvary-Schaefer N. Advances in treating insomnia. Cleve Clin J Med. Apr 2007;74(4):251-2, 255-8, 261-2 passim. [Medline]. 6. Morin AK, Jarvis CI, Lynch AM. Therapeutic options for sleep-maintenance and sleep-onset insomnia. Pharmacotherapy. Jan 2007;27(1):89-110. [Medline]. 7. Passarella S, Duong MT. Diagnosis and treatment of insomnia. Am J Health Syst Pharm. May 15 2008;65(10):927-34. [Medline]. 8. Edinger JD, Krystal AD. Subtyping primary insomnia: is sleep state misperception a distinct clinical entity?. Sleep Med Rev. Jun 2003;7(3):203-14. [Medline]. 9. [Guideline] Bloom HG, Ahmed I, Alessi CA, Ancoli-Israel S, Buysse DJ, Kryger MH, et al. Evidence-Based Recommendations for the Assessment and Management of Sleep Disorders on Older Adults. JAGS. 2009;57:761-789. 10. Cooke JR, Ancoli-Israel S. Sleep and its disorders in older adults. Psychiatr Clin North Am. Dec 2006;29(4):1077-93; abstract x-xi. [Medline]. 11. McCall WV, Erman M, Krystal AD, Rosenberg R, Scharf M, Zammit GK, et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin. Sep 2006;22(9):1633-42. [Medline]. 12. Reynolds CF 3rd, Buysse DJ, Miller MD, Pollock BG, Hall M, Mazumdar S. Paroxetine treatment of primary insomnia in older adults. Am J Geriatr Psychiatry. Sep 2006;14(9):803-7. [Medline]. 13. Sateia MJ. Update on sleep and psychiatric disorders. Chest. May 2009;135(5):1370-9. [Medline]. 14. http://meded.ucsd.edu/clinicalmed/index.htm [database online]. California: University of California, San Diego; 1997-2009. Updated 8/16/2008. 15. Sivertsen B, Omvik S, Havik OE, Pallesen S, Bjorvatn B, Nielsen GH, et al. A comparison of actigraphy and polysomnography in older adults treated for chronic primary insomnia. Sleep. Oct 1 2006;29(10):1353-8. [Medline]. 16. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. Oct 15 2008;4(5):487-504. [Medline]. [Full Text]. 17. Panossian LA, Avidan AY. Review of sleep disorders. Med Clin North Am. Mar 2009;93(2):407-25, ix. [Medline]. 18. [Guideline] Hailey D, Tran K, Dales R, Mensinkai S, McGahan L. Recommendations and supporting evidence in guidelines for referral of patients to sleep laboratories. Sleep Med Rev. Aug 2006;10(4):287-99. [Medline]. 19. Borja NL, Daniel KL. Ramelteon for the treatment of insomnia. Clin Ther. Oct 2006;28(10):1540-55. [Medline]. 20. Almeida Montes LG, Ontiveros Uribe MP, Corts Sotres J, Heinze Martin G. Treatment of primary insomnia

10 de 11

10/09/11 01:15

Primary Insomnia

http://emedicine.medscape.com/article/291573-overview

with melatonin: a double-blind, placebo-controlled, crossover study. J Psychiatry Neurosci. May 2003;28(3):191-6. [Medline]. [Full Text]. 21. Croom KF, Perry CM, Plosker GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs. 2009;23(5):427-52. [Medline]. 22. Bloom HG, Ahmed I, Alessi CA, Ancoli-Israel S, Buysse DJ, Kryger MH, et al. Evidence-based recommendations for the assessment and management of sleep disorders in older persons. J Am Geriatr Soc. May 2009;57(5):761-89. [Medline]. [Full Text]. 23. Cotroneo A, Gareri P, Nicoletti N, Lacava R, Grassone D, Maina E, et al. Effectiveness and safety of hypnotic drugs in the treatment of insomnia in over 70-year old people. Arch Gerontol Geriatr. 2007;44 Suppl 1:121-4. [Medline]. 24. Rosenberg R, Seiden DJ, Hull SG, Erman M, Schwartz H, Anderson C, et al. APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia. Sleep. Dec 1 2008;31(12):1663-71. [Medline]. [Full Text]. 25. Teegarden BR, Al Shamma H, Xiong Y. 5-HT(2A) inverse-agonists for the treatment of insomnia. Curr Top Med Chem. 2008;8(11):969-76. [Medline]. 26. Farber R, Burke J, Ross D. Indiplon in the Treatment of Chronic Insomnia in Elderly Women. Obstet Gynecol. May 2006;107(4)(suppl). 27. Marrs JC. Indiplon: a nonbenzodiazepine sedative-hypnotic for the treatment of insomnia. Ann Pharmacother. Jul 2008;42(7):1070-9. [Medline]. 28. Scharf M, Rogowski R, Hull S, Cohn M, Mayleben D, Feldman N, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: A randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry. Oct 7 2008;[Medline]. 29. Blanger L, Morin CM, Langlois F, Ladouceur R. Insomnia and generalized anxiety disorder: effects of cognitive behavior therapy for gad on insomnia symptoms. J Anxiety Disord. 2004;18(4):561-71. [Medline]. 30. Edinger JD, Wohlgemuth WK, Radtke RA, Coffman CJ, Carney CE. Dose-response effects of cognitivebehavioral insomnia therapy: a randomized clinical trial. Sleep. Feb 1 2007;30(2):203-12. [Medline]. 31. Morin CM, Vallires A, Guay B, Ivers H, Savard J, Mrette C, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA. May 20 2009;301(19):2005-15. [Medline].

11 de 11

10/09/11 01:15